CytomX Therapeutics To Present Preclinical Data For Conditionally Activated Interferon Alpha-2b At The SITC 2023 Annual Meeting

+1.87%

CytomX Therapeutics, Inc.

CTMX

1.09

+1.87%

- IND filing for CX-801 anticipated by the end of 2023 -

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced that preclinical data supporting CX-801, its conditionally activated cytokine program, will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, California.

Details for the poster presentation are as follows:

Presentation Title: Conditionally activated IFNa induces an inflammatory tumor microenvironment in preclinical models and increases efficacy in combination with checkpoint blockade

Abstract Number: 1064

Poster Hall A

Session Date and Time: November 4, 2023, 9:00 am - 8:30 pm PT

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.